To the Editor:

Patients with haematological malignancies often develop secondary immunodeficiency and respiratory infections that could predispose towards bronchiectasis, and this is supported by case reports and a previous small case series of 22 patients \[[@C1]--[@C4]\]. To improve understanding of this association we performed a retrospective review of patients with clinically significant bronchiectasis (defined as radiological evidence of bronchiectasis plus chronic productive cough or recurrent respiratory tract infections requiring antibiotic therapy) and haematological malignancy attending our respiratory clinic at a UK teaching hospital between January 2014 and April 2018. Patients were investigated according to the British Thoracic Society guideline \[[@C5]\]. Bronchiectasis onset was defined as the computed tomography (CT) scan date showing bronchiectasis closest to when the clinical diagnosis was confirmed. 18.7% of patients were followed up for 1 year, 54.7% for 5 years, 20% for 10 years and 6.7% for \>10 years. Data were extracted from electronic patient records under National Health Service research ethics committee approval 18/SC/0592 and analysed using SPSS version 22 (IBM, Chicago, IL, USA). For comparison between categorical variables, the Chi-squared or Fisher\'s exact tests were used as appropriate. Due to the nonparametric nature of the data, the Mann--Whitney test was used for the comparison of two continuous variables. Univariate analysis was used to identify factors associated with the number of lobes affected, IgG deficiency and mortality, and significant variables were entered alongside clinically relevant variables into a forward stepwise binary logistic regression model.

A total of 75 patients (median (interquartile range (IQR)) age 59 (27) years, 65.3% male) with haematological malignancy and clinically significant bronchiectasis were identified. None of these patients had CT scan evidence of bronchiectasis at the time of haematological malignancy diagnosis. The most prevalent haematological malignancies were non-Hodgkin\'s lymphoma (NHL) (29.3%), chronic lymphocytic leukaemia (CLL) (22.7%), acute myeloid leukaemia (AML) (16%) and Hodgkin\'s lymphoma (HL) (13.3%). Of the probable causes of bronchiectasis, 45 patients (60%) had had haematopoetic stem cell transplantation (HSCT), of which 37 (82.2%) were allografts. 37 patients (50.7%) were IgG deficient (IgG \<7 g·L^−1^, median (IQR) IgG for all patients 6.5 (6.5) g·L^−1^), and 20 patients (26.7%) had both previous HSCT and IgG deficiency ([figure 1a](#F1){ref-type="fig"}). For the remaining 13 patients, the bronchiectasis was suspected to be related to CLL (n=5), intrapulmonary lymphoma (n=2) or post-radiotherapy (n=1), and unknown in five. All patients with AML, acute lymphocytic leukaemia (ALL), or multiple myeloma (MM) had had HSCT, compared to 60% of HL, 55.5% of NHL and 16.7% for CLL patients. 21 out of 45 (46.6%) HSCT patients were diagnosed with pulmonary graft *versus* host disease (pGVHD) and these patients were younger than those without pGVHD (age 57 (19) *versus* 66 (23) years), p=0.015). The median (IQR) time to development of bronchiectasis was 5 (7) years from diagnosis of haematological malignancy and developed faster in patients post-HSCT (3 (20) years, 14 (31.1%) within 1 year) or treated with rituximab (4 (12) years, 14 (40%) within 1 year) compared to all patients (5 (7) years, 10 (13.3%) within 1 year). Most patients had cylindrical bronchiectasis (73 out of 75, 97.3%), with one having cystic bronchiectasis and another one varicose bronchiectasis. 40 patients (53.3%) had bronchiectasis affecting three or more lobes, and this was associated with HSCT (OR 4.00 (95% CI 1.50--10.66), p=0.006) and pGVHD (OR 5.73 (95% CI 1.70--19.31), p=0.005). In a binary logistic regression model including age, haematological malignancy, HSCT and pGVHD, only pGVHD maintained an association with three or more lobes affected (OR 6.7 (95% CI 1.2--36.6), p=0.028).

![a) Potential aetiology of bronchiectasis in individuals with haematolgoical malignancy. b) Proportion of patients with onset of clinically significant bronchiectasis within 3 years of haematological diagnosis according to haematological diagnosis (n=75). c) Proportion of patients with IgG deficiency according to haematological diagnosis (n=73). d) Kaplan--Meier survival analysis of patients with haematological malignancy from the time of bronchiectasis diagnosis (mean survival time of 3329 days (95% CI 2771--3888 days). Unadjusted hazard ratios (HRs) for e) age (age ≤40 years: HR 0.104 (95% CI 0.02--0.84), p=0.034; age 41--60 years: HR 0.90 (95% CI 0.35--2.24), p=0.804) and f) forced expiratory volume in 1 s (FEV~1~) (FEV~1~ \<40% pred: HR 4.27 (95% CI 1.29--14.09), p=0.017; FEV~1~ 41--80% pred: HR 2.12 (95% CI 0.71--6.34), p=0.180). Age-adjusted HRs for g) haematological diagnosis for haematopoietic stem cell transplant (HSCT) (HR 3.94 (95% CI 1.03--15.14), p=0.046) and h) number of lobes affected (HR 2.70 (95% CI 1.00--7.34), p=0.051). pGVHD: pulmonary graft *versus* host disease; ALL: acute lymphocytic leukaemia; AML: acute myeloid leukaemia; CLL: chronic lymphocytic leukaemia; HL: Hodgkin\'s lymphoma; MM: multiple myeloma; NHL: non-Hodgkin\'s lymphoma.](00166-2019.01){#F1}

12 (16%) patients were colonised with bacterial pathogens, including seven (9.3%) with *Pseudomonas aeruginosa*. Eight colonised patients had IgG deficiency (21.6%) *versus* three with normal IgG levels (8.3%) (p=0.113) and the odds ratio for bacterial colonisation in those with IgG deficiency was 4.28 (95% CI 0.89--20.49) (p=0.069) after adjusting for rituximab treatment. 17 patients (22.7%) had a past medical history of COPD or asthma. Smoking history was available for 73 patients (92.3%), with 62% never smokers, 33% ex-smokers and 5% current smokers. Lung function values were available for 65 patients; mean±[sd]{.smallcaps} forced expiratory volume in 1 s (FEV~1~) and forced vital capacity (FVC) were similar to that obtained by replacing missing values by multiple imputation (74.9±24.8% *versus* 75.4±24.9% pred and 86.7±20.8% *versus* 87.7±21.6% pred, respectively). Airflow limitation (FEV~1~ \<80% pred) was present in 55% of patients, with patients with pGVHD having lower mean±[sem]{.smallcaps} FEV~1~ and FVC (61.3±6.6% *versus* 80.9±3.7% pred, p=0.003; and 77.8±5.3% *versus* 91.7±3.5% pred, p=0.018) and patients with bacterial colonisation having lower mean±[sem]{.smallcaps} FEV~1~ (56.4±8.3% *versus* 79.1±3.8% pred, p=0.012).

IgG deficiency was associated with the type of haematological malignancy (p=0.007) and rituximab treatment; AML and HL patients were less likely (5.7% *versus* 26.3% and 2.9% *versus* 22.5% respectively, p\<0.05) ([figure 1c](#F1){ref-type="fig"}) and patients treated with rituximab were more likely (70.3% *versus* 29.7%, p\<0.001; OR 6.15 (95% CI 2.23--16.95), p\<0.001) to have IgG deficiency. 36 (48%) patients had rituximab treatment, including all patients with CLL, 72.7% with NHL, 30% with HL and 10% with MM.

The mortality in the cohort was high at 26.7% (20 out of 75) with 1-, 5- and 10-year survival following diagnosis of bronchiectasis of 82%, 65% and 59% ([figure 1d](#F1){ref-type="fig"}). Nonsurvivors had a median (IQR) survival of 324 (951) days, with the majority of patients post-HSCT dying within 2 years of the bronchiectasis diagnosis (76.9% *versus* 42.9% of the non-HSCT patients, p=0.0001). In a binary logistic regression model including age, haematological diagnosis, HSCT, pGVHD, IgG deficiency, FEV~1~ % pred and number of lobes affected, only age (OR 1.14 (95% CI 1.03--1.27), p=0.016) and FEV~1~ (OR 0.91 (95% CI 0.84--0.99, p=0.033) were associated with overall mortality. Univariate analysis demonstrated that survival was improved in patients ≤40 years old and reduced in patients with FEV~1~ \<40% pred ([figure 1e](#F1){ref-type="fig"} and f) \[[@C6]\]. In a Cox regression model including age, haematological malignancy, HSCT, pGVHD, bacterial colonisation, FEV~1~ % pred and number of lobes, only age (hazard ratio (HR) 1.07 (95% CI 1.03--1.12), p=0.001), FEV~1~ % pred (HR 0.96 (95% CI 0.94--0.98), p\<0.001) and number of lobes affected (HR 3.53 (95% CI 1.27--9.81), p=0.016) were significantly associated with survival duration ([figure 1g](#F1){ref-type="fig"} and h).

This is the largest reported study of patients with bronchiectasis and haematological malignancy, and although retrospective, the data provide insight into the development of bronchiectasis in these patients. Our cohort had a male predominance, whereas non-CF bronchiectasis usually has a female predominance \[[@C7]\], probably reflecting that myeloid and lymphoid malignancies are more common in males \[[@C8]\]. Bronchiectasis in this cohort seemed to develop due to different mechanisms, either acquired IgG deficiency (mainly in patients with CLL or NHL) or allograft HSCT (47% of whom had pGVHD compared to \<10% in all allograft HSCT patients) \[[@C9]\], but with some rarer causes. There was a strong association of rituximab treatment with IgG deficiency, and we suggest that there should be a high index of suspicion for bronchiectasis in patients with CLL and NHL who have received rituximab. Haematology patients frequently have multiple CT scans, allowing the timing of bronchiectasis development to be identified, and this showed the disease can develop surprisingly rapidly, frequently within a year in patients with IgG deficiency or after HSCT. Overall mortality was high, largely related to the high proportion of HSCT patients who died within 2 years of the diagnosis of bronchiectasis. Whether bronchiectasis increased mortality and was a cause of death in these patients or is just a marker for those with a poorer prognosis is not clear. Overall, our data suggest that patients with haematological malignancy can rapidly develop bronchiectasis, especially those receiving rituximab or allograft HSCT, and this disease may make a significant contribution to their morbidity and perhaps mortality.
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